On Tuesday, Revolution Medicines Inc (NASDAQ: RVMD) opened lower -1.46% from the last session, before settling in for the closing price of $38.37. Price fluctuations for RVMD have ranged from $29.17 to $62.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -27.80% annually for the last half of the decade. Company’s average yearly earnings per share was noted -31.53% at the time writing. With a float of $161.88 million, this company’s outstanding shares have now reached $186.26 million.
In an organization with 534 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 45.12%, operating margin of -301.78%, and the pretax margin is -266.93%.
Revolution Medicines Inc (RVMD) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Revolution Medicines Inc is 13.09%, while institutional ownership is 93.58%. The most recent insider transaction that took place on Jun 20 ’25, was worth 75,736. In this transaction General Counsel of this company sold 1,912 shares at a rate of $39.61, taking the stock ownership to the 54,093 shares. Before that another transaction happened on Jun 20 ’25, when Company’s Officer proposed sale 1,912 for $39.93, making the entire transaction worth $76,346.
Revolution Medicines Inc (RVMD) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -31.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.61% during the next five years compared to -27.80% drop over the previous five years of trading.
Revolution Medicines Inc (NASDAQ: RVMD) Trading Performance Indicators
Check out the current performance indicators for Revolution Medicines Inc (RVMD). In the past quarter, the stock posted a quick ratio of 13.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.00, a number that is poised to hit -1.12 in the next quarter and is forecasted to reach -5.01 in one year’s time.
Technical Analysis of Revolution Medicines Inc (RVMD)
Let’s dig in a bit further. During the last 5-days, its volume was 1.61 million. That was inferior than the volume of 1.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 62.38%.
During the past 100 days, Revolution Medicines Inc’s (RVMD) raw stochastic average was set at 59.59%, which indicates a significant increase from 37.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.34 in the past 14 days, which was lower than the 1.70 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.23, while its 200-day Moving Average is $43.01. However, in the short run, Revolution Medicines Inc’s stock first resistance to watch stands at $38.93. Second resistance stands at $40.06. The third major resistance level sits at $40.66. If the price goes on to break the first support level at $37.20, it is likely to go to the next support level at $36.60. The third support level lies at $35.47 if the price breaches the second support level.
Revolution Medicines Inc (NASDAQ: RVMD) Key Stats
There are currently 186,268K shares outstanding in the company with a market cap of 7.04 billion. Presently, the company’s annual sales total 0 K according to its annual income of -600,090 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -213,420 K.
